Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04268199 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Study acronym: EASE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: May 2025 to Dec 2026
    • Collaborators shortened, about 6 words
    v9
  2. Study sites: 1 to 2
    • Collaborator revised
    v8
  3. Collaborator revisedv7
  4. Primary completion date: May 2024 to May 2025
    • Study completion date: May 2026 to May 2025
    v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Mar 2022 to May 2024
    • Study completion date: Mar 2022 to May 2026
    v4
  2. Site contact updatedv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2020 to May 29, 2020
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
Trial Details
NCT Number NCT04268199
Lead Sponsor AHS Cancer Control Alberta
Conditions
(from sponsor)		 Myeloma, Myeloma Multiple
Related terms Multiple Myeloma, Neoplasms, Plasma Cell
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov